Your browser doesn't support javascript.
loading
Oncotype DX® in breast cancer patients: clinical experience, outcome and follow-up-a case-control study.
Rath, Michelle G; Uhlmann, Lorenz; Fiedler, Marita; Heil, Joerg; Golatta, Michael; Dinkic, Christine; Hennigs, Andre; Schott, Sarah; Ernst, Veronika; Koch, Thorsten; Sohn, Christof; Brucker, Cosima; Rom, Joachim.
Afiliación
  • Rath MG; Department of Gynecology and Obstetrics, University of Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
  • Uhlmann L; Department of Gynecology and Obstetrics, Paracelsus Medical University, Prof.-Ernst-Nathan Strasse 1, 90419, Nuremberg, Germany.
  • Fiedler M; Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 305, 69120, Heidelberg, Germany.
  • Heil J; Department of Gynecology and Obstetrics, Paracelsus Medical University, Prof.-Ernst-Nathan Strasse 1, 90419, Nuremberg, Germany.
  • Golatta M; Department of Gynecology and Obstetrics, University of Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
  • Dinkic C; Department of Gynecology and Obstetrics, University of Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
  • Hennigs A; Department of Gynecology and Obstetrics, University of Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
  • Schott S; Department of Gynecology and Obstetrics, University of Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
  • Ernst V; Department of Gynecology and Obstetrics, University of Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
  • Koch T; Department of Gynecology and Obstetrics, Paracelsus Medical University, Prof.-Ernst-Nathan Strasse 1, 90419, Nuremberg, Germany.
  • Sohn C; Department of Gynecology and Obstetrics, Paracelsus Medical University, Prof.-Ernst-Nathan Strasse 1, 90419, Nuremberg, Germany.
  • Brucker C; Department of Gynecology and Obstetrics, University of Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
  • Rom J; Department of Gynecology and Obstetrics, Paracelsus Medical University, Prof.-Ernst-Nathan Strasse 1, 90419, Nuremberg, Germany.
Arch Gynecol Obstet ; 297(2): 443-447, 2018 02.
Article en En | MEDLINE | ID: mdl-29236174
PURPOSE: Breast cancer is the leading cause of death from cancer in women and the most common cancer in the world [1]. To date, many patients with estrogen-receptor-positive (ER+) breast cancer are overtreated with chemotherapy when the rationale for adjuvant chemotherapy is based on clinicopathologic parameters. Different studies were able to demonstrate that a 21-gene expression assay (Oncotype DX® Genomic Health, Redwood City, CA) can predict the benefit from adjuvant chemotherapy in ER+ breast cancers [2, 3] and provide additional prognostic information independent of clinicopathological features [4]. RESULTS: Data from all patients with ER+ Her2neu- breast cancer undergoing Oncotype DX® testing between 2011 and 2014 at a tertiary referral center in Germany were analyzed. Oncotype DX® was performed in 69 cases, in 2 cases data were missing and in 3 cases Oncotype DX® could not be performed by the company. The results showed a low risk in 39 cases, an intermediate risk in 22 cases and a high risk in 3 cases. Based on Oncotype results, treatment recommendations were changed in 39 of 64 patients (61%). Before Oncotype DX® testing, chemotherapy was recommended in 67 patients, afterwards only in 25 patients. Data from 44 of 67 patients were matched to controls for stage, tumor grade, menopausal and hormone receptor status. Within a mean observation time of 19.7 months, cancer recurrence was observed in two patients. CONCLUSIONS: Oncotype DX® testing can be recommended for risk-tailored chemotherapy. Results should be validated in larger prospective studies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores de Estrógenos / Quimioterapia Adyuvante / Perfilación de la Expresión Génica / Recurrencia Local de Neoplasia / Antineoplásicos Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Arch Gynecol Obstet Asunto de la revista: GINECOLOGIA / OBSTETRICIA Año: 2018 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores de Estrógenos / Quimioterapia Adyuvante / Perfilación de la Expresión Génica / Recurrencia Local de Neoplasia / Antineoplásicos Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged País/Región como asunto: Europa Idioma: En Revista: Arch Gynecol Obstet Asunto de la revista: GINECOLOGIA / OBSTETRICIA Año: 2018 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Alemania